BRAF and melanoma: In patients with melanoma, the activated BRAF-mutated kinase can be inhibited by BRAF-targeting drugs, and its downstream protein mitogen-activated protein kinase kinase (MEK) can be inhibited by a MEK-targeting drug [3].